KeyNeurotek Pharmaceuticals concludes patient recruitment in a Phase IIa traumatic brain injury study with KN38-7271 on schedule
KeyNeurotek Pharmaceuticals AG, a biotechnology company focused on the development and marketing of drugs against autoim…